

226  
3/2/07

**Curriculum Vitae**  
**Loris J. Thornton, Sr., CDT, RTL**

**BUSINESS ADDRESS:**

National Clinical Research, Inc.  
2809 Emerywood Pkwy  
Suite 140  
Richmond, VA 23294  
804-672-2133 ext. 54

**EDUCATION**

1969                      Maggie L. Walker High School

**PROFESSIONAL EXPERIENCE**

1994 – present            DEXA Technician/Clinical Research Assistant  
National Clinical Research  
Richmond, VA

1986 – 1993              Research Assistant  
Virginia Commonwealth University  
Richmond, VA

1983 – 1985              Ward Clerk  
Medical College of Virginia  
Richmond, VA

**RESEARCH TRAINING**

Radiation Safety Training  
Computer training at Medical College of Virginia  
Blood Pressure Certification training by Bristol Myers Squibb  
QDR1000 Bone Densitometer operator certification (training by Hologic)  
QDR4500 Bone Densitometer operator certification (training by Hologic)  
Certified by the International Society for Clinical Densitometry  
Licensed by the Commonwealth of Virginia

**CLINICAL RESEARCH EXPERIENCE**

ADAS Rater

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of SGS742 in Subjects with Mild to Moderate Alzheimer's Disease, Saegis/INC Research (Protocol SGS742-CL02), Mar04.

A randomized, multicenter, double-blind, placebo-controlled, 18-month study of the efficacy of Xaliproden in patients with mild-to-moderate dementia of the Alzheimer's type, Sanofi-Synthelabo (Protocol EFC2724), Aug04.

## Curriculum Vitae

Loris J. Thornton, CDT, RTL

Page 2 of 6

An 80-week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease, Pfizer/ICON (Protocol A2581078), Dec04.

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment, Johnson & Johnson (Protocol GAL-MCI-301), Apr03 – Apr04.

A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probably Alzheimer's disease, Parexel/Janssen Research Foundation (Protocol GAL-INT-18), Mar01 – Nov03.

### DEXA Technician

A four-year, double-blind, multi-center, placebo-controlled study of the effects of three different doses of Calcimar on bone mineral density, stature, and biochemical markers of bone turnover in women with established post menopausal osteoporosis, Corning Besselaar/Rhone Poulenc Rorer (Protocol RG-83853-402), Oct95 -Oct99.

Efficacy and safety evaluation of Fempatch (transdermal 17B estradiol) on biochemical bone markers in postmenopausal women, Parke Davis, Dec96 - Dec97.

A randomized, double-blind, placebo controlled, parallel, multi-center, study to assess the safety and efficacy of transdermal 17B-estradiol/norethindrone acetate for relief of menopausal vasomotor systems and reduction of endometrial hyperplasia, Wyeth-Ayerst (Protocol 0802D1-324-US), Feb97 – Feb00.

A randomized, modified, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and the dose-response of a Vivelle in the prevention of postmenopausal bone loss, Ciba-Geigy Corporation (Protocol 035), Oct97 – Dec98.

A double-blind, randomized, multi-center, placebo-controlled trial of 0.5 and 1.25 mg of Levormeloxifene for the treatment of postmenopausal osteoporosis, NovoNordisk (Protocol LEV/PD/16/USA), Dec97 – Sep01.

A double-blind, randomized, multi-center, placebo-controlled trial of Levormeloxifene and Prempro for the prevention for postmenopausal osteoporosis, NovoNordisk (Protocol LEV/PD/15/USA), Dec97 – Sep01.

A randomized, double-blind, active- and placebo-controlled, parallel group, multi-center study assessing the safety and protective effect on the endometrium of four dosage combinations of Norethindrone acetate plus Ethinyl estradiol, Parke Davis (Protocol 376-401-47), Jan98 - Jun99.

Phase II, double-blind placebo-controlled trial of the safety, toleration and efficacy of CP-336,156 and ralozifene 60 mg/day for the prevention of bone loss in postmenopausal women, Pfizer (Protocol 218-102), Feb98 – Aug01.

